Drugs

Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma

Photo of Tom Powles taken from bartscancer.london

Apr 11, 2024, 08:13

Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma

Tom Powles, Director of Barts Cancer Center, recently shared on X:

“Trial in progress: The HER2/MMAE Antibody Drug Conjugates, Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma (HER2+ve). DVs efficacy looks increased also with Immuno-oncology (IO). Toxic profile looks distinct with? Decreased skin toxicity? EAU24 results will be considered in the context of other positives first line studies.”

Source: Tom Powles/X

Antibody drug conjugates Avelumab Barts Cancer Center cancer chemotherapy Disitimab EAU24 HER2 Immuno-oncology (IO) OncoDaily Oncology pembrolizumab Skin Toxicity Tom Powles Toxic profile Trial Vedotin

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 9

Shannon Miller and Ovarian Cancer: How She Went Against, How She Survived, and More

ASTRO Overview: Everything You Need to Know About the Leading Radiation Oncology Society

Kamala Harris vs Donald Trump on Cancer: From Cancer Moonshot to Right to Act, Funding, Research and Future

Dr. Richard Pazdur: 25 Years of Transforming Oncology Drug Development at the FDA

Special Coverage